| Identification | Back Directory | [Name]
ABI-H0731 | [CAS]
2090064-66-5 | [Synonyms]
ABI-H0731
antiviral,Inhibitor,Vebicorvir,inhibit,Hepatitis B virus,HBV,CHB,DBT
11-oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide-5,5-dioxide
Dibenzo[b,f][1,4]thiazepine-8-carboxamide, 10,11-dihydro-11-oxo-N-[[2-(trifluoromethyl)-5-thiazolyl]methyl]-, 5,5-dioxide | [Molecular Formula]
C19H12F3N3O4S2 | [MDL Number]
MFCD32856555 | [MOL File]
2090064-66-5.mol | [Molecular Weight]
467.44 |
| Chemical Properties | Back Directory | [Boiling point ]
566.3±50.0 °C(Predicted) | [density ]
1.557±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (213.93 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.14±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM[1]. | [in vivo]
After i.v. administration, the drug rapidly distributes and decayes in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86 ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow, in mouse, rat, dog, and monkey, respectively[1].
| [storage]
Store at -20°C | [References]
[1] Qi Huang, et al. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20. DOI:10.1128/AAC.01463-20 |
|
|